D
D. Geers
Publications - 19
Citations - 465
D. Geers is an academic researcher. The author has contributed to research in topics: Medicine & Immunology. The author has an hindex of 6, co-authored 19 publications receiving 465 citations.
Papers
More filters
Journal ArticleDOI
Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
Corine H. GeurtsvanKessel,D. Geers,Katharina S. Schmitz,Anna Z Mykytyn,Mart M. Lamers,Susanne Bogers,Sandra M.J. Scherbeijn,L. Gommers,Roos S G Sablerolles,N. Nieuwkoop,Laurine C Rijsbergen,Laura J. A. van Dijk,J. de Wilde,Kimberley Alblas,Tim I Breugem,Bart J. A. Rijnders,Herbert de Jager,Daniela Weiskopf,P. H. M. van der Kuy,Alessandro Sette,Marion Koopmans,Alba Grifoni,Bart L. Haagmans,Rory D. de Vries +23 more
TL;DR: This study shows that vaccinated individuals retain T cell immunity to the SARS-CoV-2 Omicron variant, potentially balancing the lack of neutralizing antibodies in preventing or limiting severe COVID-19 cases.
Journal ArticleDOI
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
Roos S G Sablerolles,Wim J. R. Rietdijk,Abraham Goorhuis,Douwe F. Postma,Leo G. Visser,D. Geers,Katharina S. Schmitz,Hannah M. Garcia Garrido,Marion Koopmans,Virgil A. S. H. Dalm,Neeltje A. Kootstra,Anke Huckriede,Melvin Lafeber,Debbie van Baarle,Corine H. GeurtsvanKessel,Rory D. de Vries,P. H. M. van der Kuy +16 more
TL;DR: Homologous or heterologous booster vaccination resulted in higher levels of S-specific binding antibodies, neutralizing antibodies, and T-cell responses than a single Ad26.COV2.S vaccination, and the strongest responses occurred after boosting with mRNA-based vaccines.
Journal ArticleDOI
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
Leanne P M van Leeuwen,Corine H. GeurtsvanKessel,Pauline M. Ellerbroek,Godelieve J. de Bree,Judith Potjewijd,Abraham Rutgers,Hetty Jolink,Frank L. van de Veerdonk,Eric C. M. van Gorp,F. de Wilt,Susanne Bogers,L. Gommers,D. Geers,Anke H W Bruns,Helen L. Leavis,Jelle W. van Haga,Bregtje A. Lemkes,Annelou L.I.P. van der Veen,S.F.J. de Kruijf-Bazen,Pieter van Paassen,Karina de Leeuw,Annick A. J. M. van de Ven,Petra H. Verbeek-Menken,Annelies van Wengen,Sandra M. Arend,Anja J. Ruten-Budde,Marianne W. van der Ent,P. M. van Hagen,Rogier W. Sanders,Marloes Grobben,Karlijn van der Straten,Judith A. Burger,Meliawati Poniman,Stefan Nierkens,Marit J. van Gils,Rory D. de Vries,Virgil A. S. H. Dalm +36 more
TL;DR: In a prospective, controlled, multicenter study, 505 patients with inborn errors of immunity (IEI) (CVID), isolated or undefined antibody deficiencies, X-linked agammaglobulinemia, combined B- and T-cell immunodeficiency, phagocyte defects, and 192 controls were included as discussed by the authors .
Journal ArticleDOI
Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial
Marcia M. L. Kho,A. Lianne Messchendorp,S. C. Frölke,C. Imhof,Vera Jch Koomen,S. R. K. Malahe,Priya Vart,D. Geers,Rory D. de Vries,Corine H. GeurtsvanKessel,Carla C. Baan,Renate G. van der Molen,Dimitri A. Diavatopoulos,Ester B. M. Remmerswaal,Debbie van Baarle,Rob van Binnendijk,Gerco den Hartog,Aiko P. J. de Vries,Ron T. Gansevoort,Frederike J. Bemelman,Marlies E.J. Reinders,Jan-Stephan F. Sanders,Luuk B. Hilbrands,Alferso C. Abrahams,Marije C. Baas,P. Bouwmans,M A G J ten Dam,L. Gommers,Dorien Standaar,Marieke van der Heiden,Yvonne Adema,Marieken J. Boer-Verschragen,Wouter B Mattheussens,Ria L. A. Philipsen,Djenolan Van Mourik,Susanne Bogers,Laura J. A. van Dijk,Nynke Y. Rots,Gaby Smits,Marjan Kuijer,Marc H Hemmelder +40 more
TL;DR: Repeated vaccination increases SARS-CoV-2-specific antibodies in KTRs, without further enhancement by use of a higher dose, a heterologous vaccine, or 2 weeks discontinuation of mycophenolate mofetil or mycopenolic acid.
Journal ArticleDOI
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study
Kathryn S Hensley,Marlou J Jongkees,D. Geers,Corine H. GeurtsvanKessel,Yvonne M. Mueller,Virgil A. S. H. Dalm,Grigorios Papageorgiou,Hanka Steggink,Alicja Górska,Susanne Bogers,Jan G den Hollander,Wouter F W Bierman,L. B. S. Gelinck,Emile F. Schippers,Heidi S. M. Ammerlaan,M. van der Valk,Marit G. A. van Vonderen,Corine E Delsing,Elisabeth H. Gisolf,Anke H W Bruns,Fanny N. Lauw,Marvin A H Berrevoets,Kim C. E. Sigaloff,Robin Soetekouw,Judith Branger,Quirijn de Mast,A. Lammers,Selwyn H. Lowe,Rory D. de Vries,Peter D. Katsikis,Bart J. A. Rijnders,Kees Brinkman,Anna H. Roukens,Casper Rokx +33 more
TL;DR: After vaccination with BNT162b2 or mRNA-1273, anti-spike SARS-CoV-2 antibody levels were reduced in PLWH compared to HIV- negative controls, and to reach and maintain the same serological responses as HIV-negative controls, additional vaccinations are probably required.